
|Articles|February 26, 2014
- NSCLC (Issue 2)
- Volume 2
- Issue 1
PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.
Advertisement
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.
Read more aboutfrontline treatment considerations for lung cancer > >
Articles in this issue
over 12 years ago
Crizotinib Resistance in ALK-Positive Lung Cancerover 12 years ago
Clinical Update: ALK-Positive NSCLCover 12 years ago
Treating Older Patients With NSCLCover 12 years ago
Treatment of Elderly Patients With NSCLCover 12 years ago
Current Challenges in Molecular Testing in NSCLCover 12 years ago
Individualized Maintenance Therapy for NSCLCover 12 years ago
Frontline Treatment Considerations in Non-Small Cell Lung CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5

































